Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

27.03.20	Sanofi: Sarclisa Gets Positive CHMP Opinion To Treat Multiple Myeloma (RTTNews)
27.03.20	Sanofi, Translate Bio To Develop Novel MRNA Vaccine Candidate Against COVID-19 (RTTNews)
27.03.20	Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19 (GlobeNewswire)
24.03.20	Sanofi successfully prices EUR 1.5 billion of bond issue (GlobeNewswire)
24.03.20	Why Consider These 2 Stocks When Markets Are Crashing? (RTTNews)
17.03.20	Regeneron Discovers Antibodies For COVID-19 Treatment (RTTNews)
16.03.20	Sanofi, Regeneron Begin Kevzara Clinical Trial For Severe COVID-19 - Quick Facts (RTTNews)
05.03.20	Sanofi : Filing of the 2019 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report (GlobeNewswire)
04.03.20	Sanofi's Board of Directors proposes the appointment of Rachel Duan and Lise Kingo as independent directors (GlobeNewswire)
03.03.20	RCEL On The Move, FTSV Acquired, NCNA On Watch, FDA Nod For SNY, COVID-19 Update (RTTNews)
02.03.20	Sanofi : FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma (GlobeNewswire)
24.02.20	Sanofi To Create European Company To Provide Active Pharmaceutical Ingredients (RTTNews)
24.02.20	Sanofi to create new industry leading European company to provide active pharmaceutical ingredients (API*) (GlobeNewswire)
18.02.20	Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine (GlobeNewswire)
06.02.20	Regeneron, Sanofi To Restructure Antibody Collaboration For Kevzara, Praluent (RTTNews)
06.02.20	Sanofi Q4 Business Profit Rises; Sales Up 4.7% At CER - Quick Facts (RTTNews)
06.02.20	Sanofi Brain-penetrant BTK Inhibitor Meets Primary Endpoint Of Phase 2 Trial (RTTNews)
06.02.20	Sanofi : Sanofi brain-penetrant BTK inhibitor meets primary endpoint of Phase 2 trial in relapsing multiple sclerosis (GlobeNewswire)
30.01.20	Sanofi: Trials Show Positive Topline Results In Acid Sphingomyelinase Deficiency (RTTNews)
30.01.20	Sanofi : Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency (GlobeNewswire)
28.01.20	Regeneron, Sanofi: FDA To Review SBLA For Dupixent - Quick Facts (RTTNews)
28.01.20	Sanofi : FDA accepts for priority review Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis (GlobeNewswire)
23.01.20	Sanofi : Sanofi Completes Acquisition of Synthorx, Inc. (GlobeNewswire)
20.01.20	Sanofi Reports Expiration Of HSR Waiting Period For Synthorx Deal - Quick Facts (RTTNews)
20.01.20	Sanofi : Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Synthorx (GlobeNewswire)
09.01.20	Sanofi : Availability of the Pre-quarterly Results Communication (GlobeNewswire)
23.12.19	Sanofi Commences Tender Offer To Buy Synthorx - Quick Facts (RTTNews)
23.12.19	Sanofi commences tender offer for acquisition of Synthorx, Inc. (GlobeNewswire)
10.12.19	Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab) (GlobeNewswire)
10.12.19	Sanofi Says Late-stage Trial On Sutimlimab Meets Primary, Secondary Endpoints (RTTNews)
10.12.19	Sanofi : Positive results presented from pivotal Phase 3 trial of sutimlimab in people with cold agglutinin disease (GlobeNewswire)
09.12.19	Sanofi CEO unveils new strategy to drive innovation and growth (GlobeNewswire)
09.12.19	Sanofi To Raise Pandemic Influenza Vaccine Production Supported By Federal Funds (RTTNews)
09.12.19	Sanofi Agrees To Buy Synthorx For $2.5 Bln - Quick Facts (RTTNews)
09.12.19	Sanofi : Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion (GlobeNewswire)
02.12.19	Baxter To Acquire Seprafilm Adhesion Barrier, Related Assets From Sanofi (RTTNews)
21.11.19	Sanofi :Sutimlimab Meets Primary Endpoint In Phase 3 Trial For Patients With CAD (RTTNews)
04.11.19	Sanofi : FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older (GlobeNewswire)
04.11.19	Sanofi: Positive Toujeo Study Results In 6 To 17 Years With Type 1 Diabetes (RTTNews)
04.11.19	Sanofi : Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes (GlobeNewswire)
31.10.19	Sanofi Agrees To Pay $315 Mln To Settle Contingent Value Rights Litigation (RTTNews)
29.10.19	Regeneron, Sanofi: European Commission Approves New Indication For Dupixent (RTTNews)
29.10.19	Sanofi : Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis (GlobeNewswire)
24.10.19	Drug Companies Issue Recalls For Ranitidine, Zantac In US (RTTNews)
18.10.19	Sanofi To Recall Zantac In North America (RTTNews)
15.10.19	Sanofi opens its first digitally-enabled, continuous manufacturing facility; ushers in next generation of biotech manufacturing (GlobeNewswire)
01.10.19	Sanofi : Availability of the Pre-quarterly Results Communication (GlobeNewswire)
30.09.19	Sanofi : New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate c (GlobeNewswire)
20.09.19	Regeneron And Sanofi Say CHMP Adopts Positive Opinion For Dupixent (RTTNews)
20.09.19	Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	535.60	0.87 %	K V
Part Grp Hldg	1’258.00	0.56 %	K V
Novartis	92.36	0.47 %	K V
Alcon	77.84	0.28 %	K V
Holcim	88.64	0.25 %	K V
Swiss Life Hldg	717.20	-0.31 %	K V
UBS Group	27.61	-0.54 %	K V
ABB	49.20	-0.69 %	K V
Sika	226.20	-1.05 %	K V
Logitech Intl	71.00	-1.36 %	K V

mehr

16:02		Dow Jones 30 Industrial-Titel Johnson Johnson-Aktie: So viel Verlust hätte eine Johnson Johnson-Investition von vor 3 Jahren eingebracht
15:58		Minuszeichen in Europa: STOXX 50 legt am Mittwochnachmittag den Rückwärtsgang ein
15:58		Schwache Performance in Zürich: SLI nachmittags im Minus
15:58		Mittwochshandel in Zürich: SPI kaum bewegt
15:58		Handel in Europa: So bewegt sich der Euro STOXX 50 aktuell
15:58		FTSE 100 aktuell: FTSE 100 steigt am Nachmittag
15:58		Schwache Performance in Frankfurt: TecDAX zeigt sich nachmittags schwächer
15:58		XETRA-Handel: SDAX am Nachmittag freundlich

16:02

Dow Jones 30 Industrial-Titel Johnson Johnson-Aktie: So viel Verlust hätte eine Johnson Johnson-Investition von vor 3 Jahren eingebracht

15:58

Minuszeichen in Europa: STOXX 50 legt am Mittwochnachmittag den Rückwärtsgang ein

15:58

Schwache Performance in Zürich: SLI nachmittags im Minus

15:58

Mittwochshandel in Zürich: SPI kaum bewegt

15:58

Handel in Europa: So bewegt sich der Euro STOXX 50 aktuell

15:58

FTSE 100 aktuell: FTSE 100 steigt am Nachmittag